Immune Thrombocytopenic Purpura (ITP) Latest Advances

Find the Latest Research About Immune Thrombocytopenic Purpura (ITP)

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11409 publications

Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program.

Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program.

Journal: Journal of the advanced practitioner in oncology
Published: April 13, 2026

The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura.

The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura.

Journal: Expert review of hematology
Published: April 08, 2026

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.

Journal: The New England journal of medicine
Published: April 08, 2026

Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia.

Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia.

Journal: Platelets
Published: April 01, 2026

Primary Splenic Classic Hodgkin Lymphoma with Immune Thrombocytopenic Purpura and Extramedullary Hematopoiesis.

Primary Splenic Classic Hodgkin Lymphoma with Immune Thrombocytopenic Purpura and Extramedullary Hematopoiesis.

Journal: International journal of surgical pathology
Published: April 01, 2026

Abnormal expansion of peripheral helper T cells in primary immune thrombocytopenia.

Abnormal expansion of peripheral helper T cells in primary immune thrombocytopenia.

Journal: Platelets
Published: March 31, 2026

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Journal: Pharmacological research
Published: March 31, 2026

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Journal: Leukemia & lymphoma
Published: March 30, 2026

Successful combination therapy with fostamatinib and romiplostim in refractory immune thrombocytopenia 27 years after onset

Successful combination therapy with fostamatinib and romiplostim in refractory immune thrombocytopenia 27 years after onset

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: March 29, 2026

Isolated Dermal Arteriolar Thrombosis in a Pediatric Patient: A Rare Complication During Eltrombopag Therapy for Chronic Immune Thrombocytopenia.

Isolated Dermal Arteriolar Thrombosis in a Pediatric Patient: A Rare Complication During Eltrombopag Therapy for Chronic Immune Thrombocytopenia.

Journal: Pediatric blood & cancer
Published: March 25, 2026

Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management.

Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management.

Journal: Expert opinion on pharmacotherapy
Published: March 24, 2026

Solving the mystery of vaccine-induced immune thrombocytopenia and thrombosis.

Solving the mystery of vaccine-induced immune thrombocytopenia and thrombosis.

Journal: Nature reviews. Cardiology
Published: March 19, 2026
Showing 1-12 of 11,409

Last Updated: 04/28/2026